Evaluation of the predictive performance of physiologically based pharmacokinetic models for intramuscular injections of therapeutic proteins

References

• Abe T, Fujita S, Nakajima T, et al. (2010). Effects of low-intensity cycle training with restricted leg blood flow on thigh muscle volume and VO2MAX in young men. J Sports Sci Med 9:452–8.
   PubMed Web of Science ®Google Scholar
• Baxter LT, Zhu H, Mackensen DG, Jain RK. (1994). Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 54(6): 517–1528.
   PubMed Web of Science ®Google Scholar
• Cao Y, Jusko WJ. (2012). Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn 39:711–23.
   PubMed Web of Science ®Google Scholar
• Covell DG, Barbet J, Holton OD, et al. (1986). Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice “)”. Cancer Res 46:3969–78.
   PubMed Web of Science ®Google Scholar
• Davda JP, Jain M, Batra SK, et al. (2008). A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int J Immunopharmacol 8:401–13.
   PubMed Web of Science ®Google Scholar
• Ferl GZ. (2006). A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther 5:1550–8.
   PubMed Web of Science ®Google Scholar
• Flessner MF, Lofthouse J, Zakaria E-R. (1997). In vivo diffusion of immunoglobulin G in muscle: effects of binding, solute exclusion, and lymphatic removal. Am J Physiol 273:H2783–93.
   PubMedGoogle Scholar
• Food and Drug Administration. Guidance for Industry M3 (R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. Rockville (MD): The association; Feb 2013.
   Google Scholar
• Fronton L, Pilari S, Huisinga W. (2014). Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models. J Pharmacokinet Pharmacodyn 41:87–107.
   PubMed Web of Science ®Google Scholar
• Gallo JM, Vicini P, Orlansky A, et al. (2004). Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clin Cancer Res 10:8048–58.
   PubMed Web of Science ®Google Scholar
• Garg A, Balthasar JP. (2007). Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34:687–709.
   PubMed Web of Science ®Google Scholar
• Gibaldi KM, Perrier D. Noncompartmental analysis based on statistical moment theory. In: Swarbrick J, ed. Pharmacokinetics. New York: Marcel Dekker, Inc; 1982, 409–17.
   Google Scholar
• Gill KL, Gardner I, Li L, Jamei M. (2016). A bottom-up whole-body physiologically based pharmacokinetic model to mechanistically predict tissue distribution and the rate of subcutaneous absorption of therapeutic proteins. AAPSJ 18:156–70.
   PubMed Web of Science ®Google Scholar
• Griffin MP, Khan AA, Esser MT, et al. (2017). Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother 61:1–9.
   Web of Science ®Google Scholar
• Grimaldi A, Richardson C, Durbridge G, et al. (2009). The association between degenerative hip joint pathology and size of the gluteus maximus and tensor fascia lata muscles. Man Ther 14:611–7.
   PubMed Web of Science ®Google Scholar
• Holzbaur KRS, Murray WM, Gold GE, Delp SL. (2007). Upper limb muscle volumes in adult subjects. J Biomech 40:742–9.
   PubMed Web of Science ®Google Scholar
• Ibrahim R, Nitsche JM, Kasting GB. (2012). Dermal Clearance Model for epidermal bioavailability calculations. J Pharm Sci 101:2094–108.
   PubMed Web of Science ®Google Scholar
• Jockenhövel F, Fingscheidt U, Khan SA, et al. (2009). Bio and immuno-activity of FSH in serum after intramuscular injection of highly purified urinary human FSH in normal men. Clin Endocrinol (Oxf) 33:573–84.
   Google Scholar
• Jones HM, Parrott N, Jorga K, Lavé T. (2006). A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511–42.
   PubMed Web of Science ®Google Scholar
• Lagassé HAD, Alexaki A, Simhadri VL, et al. (2017). Recent advances in (therapeutic protein) drug development. F1000Res 6:113.
   PubMedGoogle Scholar
• Li L, Gardner I, Dostalek M, Jamei M. (2014). Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model. AAPS J 16:1097–109. Sep
   PubMed Web of Science ®Google Scholar
• Lipinski C. (2000). Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 44(1):235–249.
   Google Scholar
• Mannaerts BM, Geurts TB, Odink J. (1998). A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration. Hum Reprod 13:1461–4.
   PubMed Web of Science ®Google Scholar
• Munafo A, Trinchard-Lugan I, Nguyen T, Buraglio M. (1998). Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol 5:187–93.
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. JPET 283:46–58.
   PubMed Web of Science ®Google Scholar
• Offman E, Edginton AN. (2015). A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide. J Pharmacokinet Pharmacodyn 42:135–50.
   PubMed Web of Science ®Google Scholar
• Ortega H, Yancey S, Cozens S. (2014). Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites. Clin Pharmacol Drug Dev 3:57–62.
   PubMed Web of Science ®Google Scholar
• Patlak CS, Goldstein DA, Hoffman JF. (1963). The flow of solute and solvent across a two-membrane system. J Theor Biol 5:426–42.
   PubMed Web of Science ®Google Scholar
• Peters S. (2008). Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet 47:261–75.
   PubMed Web of Science ®Google Scholar
• Philippidis A. (2017). The top 15 best-selling drugs of 2016. Genetic engineering and biotechnology news [Internet]. Available from: https://www.genengnews.com/the-lists/the-top-15-best-selling-drugs-of-2016/77900868 [last accessed 8 Nov 2017].
   Google Scholar
• Plavina T, Fox EJ, Lucas N, et al. (2016). A randomized trial evaluating various administration routes of natalizumab in multiple sclerosis. J Clin Pharmacol 56:1254–62.
   PubMed Web of Science ®Google Scholar
• Reilly RM, Domingo R, Sandhu J. (1997). Oral delivery of antibodies. Future pharmacokinetic trends. Clin Pharmacokinet 32:313–23.
   PubMed Web of Science ®Google Scholar
• Renkin EM. (1977). Multiple pathways of capillary permeability. Circ Res 41:735–43.
   PubMed Web of Science ®Google Scholar
• Renkin EM. (1985). Capillary transport of macromolecules: pores and other endothelial pathways. J Appl Physiol 58:315–25.
   PubMed Web of Science ®Google Scholar
• Richter WF, Bhansali SG, Morris ME. (2012). Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J 14:559–70.
   PubMed Web of Science ®Google Scholar
• Rippe B, Haraldsson B. (1994). Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev 74:163–219.
   PubMed Web of Science ®Google Scholar
• Rocci ML, Szefler SJ, Acara M, Jusko WJ. (1981). Prednisolone metabolism and excretion in the isolated perfused rat kidney. Drug Metab Dispos 9:177–82.
   PubMed Web of Science ®Google Scholar
• Sepp A, Berges A, Sanderson A, Meno-Tetang G. (2015). Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory. J Pharmacokinet Pharmacodyn 42:97–109.
   PubMed Web of Science ®Google Scholar
• Shah DK, Betts AM. (2012). Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39:67–86.
   PubMed Web of Science ®Google Scholar
• Slakter MJ. (1965). A comparison of the Pearson Chi-Square and Kolmogorov goodness-of-fit tests with respect to validity. J Am Stat Assoc 60:854–8.
   Web of Science ®Google Scholar
• Stanton AWB, Modi S, Mellor RH, et al. (2006). A quantitative lymphoscintigraphic evaluation of lymphatic function in the swollen hands of women with lymphoedema following breast cancer treatment. Clin Sci 110:553–61.
   PubMed Web of Science ®Google Scholar
• Stanton SJ, Edelstein RS. (2009). The physiology of women’s power motive: implicit power motivation is positively associated with estradiol levels in women. J Res Pers 43:1109–13.
   Web of Science ®Google Scholar
• Supersaxo A, Hein WR, Steffen H. (1990). Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 07:167–9.
   Google Scholar
• Taylor AE, Granger DN, Brace RA. (1977). Analysis of lymphatic protein flux data. I. Estimation of the reflection coefficient and permeability surface area product for total protein. Microvasc Res 13:297–313.
   PubMed Web of Science ®Google Scholar
• Turner MR, Balu l. SV. (2018). Challenges and opportunities for the subcutaneous delivery of therapeutic proteins. 107:1247–60.
   Google Scholar
• Vaishnaw AK, TenHoor CN. (2002). Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn 29:415–26.
   PubMed Web of Science ®Google Scholar
• Vázquez H, Chávez-Haro A, García-Ubbelohde W, et al. (2005). Pharmacokinetics of a F(ab′)2 scorpion antivenom in healthy human volunteers. Toxicon 46:797–805.
   PubMed Web of Science ®Google Scholar
• Verbist L, Tjandramaga B, Hendrickx B, et al. (1984). In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother 26:881–6.
   PubMed Web of Science ®Google Scholar
• Weatherspoon D. (2016). What are intramuscular injections? Healthline [Internet]. Available from: https://www.healthline.com/health/intramuscular-injection1. [last accessed 8 Nov 2017]
   Google Scholar
• Wilson AP. (2000). Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 39:167–83.
   PubMed Web of Science ®Google Scholar
• Zhao L, Ji P, Li Z, et al. (2013). The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model. J Clin Pharmacol 53:314–25.
   PubMed Web of Science ®Google Scholar